Karyopharm Therapeutics Posts Positive Results, Beats Estimates by $0.08 and $1.49M Respectively.
May 5, 2023
Trending News ☀️
Karyopharm Therapeutics ($NASDAQ:KPTI), Inc. is a clinical-stage biopharmaceutical company that is committed to discovering, developing, and commercializing novel treatments for cancer and other serious diseases. Karyopharm Therapeutics also reported that they intend to use their cash balance to fund their clinical programs and other activities to support the development of their pipeline. Their pipeline includes several small molecule drugs that are being developed for the treatment of multiple myeloma, mantle cell lymphoma, diffuse large B-cell lymphoma, and advanced solid tumors.
Overall, Karyopharm Therapeutics posted positive results for the quarter, beating analysts’ estimates for both EPS and revenue. Investors and analysts alike are optimistic about the company’s future prospects given their strong pipeline and financial position.
Earnings
KARYOPHARM THERAPEUTICS has reported positives results in its FY2022 Q4 earning report. The report, which ended on December 31, 2022, showed that the company earned 33.58M USD in total revenue and lost 38.51M USD in net income. Compared to the previous year, KARYOPHARM THERAPEUTICS showed a 73.4% decrease in total revenue and a 199.5% decrease in net income. Their total revenue has decreased from 35.1M USD to 33.58M USD in the span of the last three years.
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Karyopharm Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 157.07 | -165.29 | -105.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Karyopharm Therapeutics. More…
| Operations | Investing | Financing |
| -149.55 | -104.26 | 193.74 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Karyopharm Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 358.17 | 374.83 | -0.15 |
Key Ratios Snapshot
Some of the financial key ratios for Karyopharm Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 56.6% | – | -89.1% |
| FCF Margin | ROE | ROA |
| -95.3% | 111.5% | -24.4% |
Market Price
On Thursday, the stock opened at $3.4 and closed at $2.8, a 24.3% plunge from the previous day’s closing price of $3.7. This significant decline in stock price indicates that investors were not satisfied with the company’s results. However, the company was able to post positive results, showing growth in revenue and income for the reported period. Karyopharm Therapeutics has taken steps to increase its presence in the market and expand its operations in order to continue to post better results in the future. Live Quote…
Analysis
At GoodWhale, we analyze KARYOPHARM THERAPEUTICS‘ fundamentals to provide you with an informed decision. Our Star Chart classifies KARYOPHARM THERAPEUTICS as a ‘rhino’, a type of company that has achieved moderate revenue or earnings growth. Therefore, investors who are looking for a company that shows potential for growth but may not be able to offer the highest returns may be interested in KARYOPHARM THERAPEUTICS. In addition, KARYOPHARM THERAPEUTICS has a low health score of 2/10, which indicates that the company is less likely to pay off debts and fund future operations. Therefore, it may be beneficial for investors to consider other investment opportunities that have higher health scores. Overall, KARYOPHARM THERAPEUTICS is strong in growth, medium in asset and weak in dividend and profitability. We believe this company is suitable for investors who are looking for potential growth while understanding the risks involved. More…
Peers
The competition among Karyopharm Therapeutics Inc, Soleno Therapeutics Inc, Neovacs SA, and Shanghai Allist Pharmaceuticals Co Ltd is fierce. All four companies are vying for a share of the market for new cancer treatments. Karyopharm Therapeutics Inc has the most experience in developing new cancer treatments, but its competitors are quickly catching up. Soleno Therapeutics Inc has the most experience in clinical trials, but Neovacs SA has the most experience in manufacturing. Shanghai Allist Pharmaceuticals Co Ltd is the only company with experience in both developing new cancer treatments and manufacturing.
– Soleno Therapeutics Inc ($NASDAQ:SLNO)
Soleno Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare cardiovascular and metabolic diseases. The company’s lead product candidate is diazoxide choline controlled-release (DCCR), a once-daily oral tablet for the treatment of primary pulmonary hypertension (PPH) and other rare cardiovascular diseases. Soleno has completed a Phase 2 clinical trial of DCCR in patients with PPH and is currently enrolling patients in a Phase 3 clinical trial. The company also has a portfolio of other product candidates in various stages of development for the treatment of diabetes and other metabolic diseases.
– Neovacs SA ($LTS:0W8U)
Headquartered in Paris, France, Neovacs is a biopharmaceutical company focused on the development of active immunotherapies for the treatment of autoimmune and inflammatory diseases. The company’s lead product candidates are IFNalpha-Kinoid and TNF-Kinoid, which are in clinical development for the treatment of systemic lupus erythematosus and rheumatoid arthritis, respectively.
– Shanghai Allist Pharmaceuticals Co Ltd ($SHSE:688578)
Shanghai Allist Pharmaceuticals Co Ltd is a pharmaceutical company that manufactures and sells drugs in China. The company has a market cap of 10.29B as of 2022 and a Return on Equity of 2.58%. Allist is a leading manufacturer of drugs in China and has a strong presence in the domestic market. The company’s products are used in the treatment of various diseases and disorders, including cancer, cardiovascular disease, and diabetes. Allist has a strong research and development capability and has a number of new drugs in its pipeline. The company is well-positioned to benefit from the growing demand for pharmaceutical products in China.
Summary
Despite these positive figures, the company’s stock price declined on the news, suggesting investors may be taking a more cautious approach to the company’s performance. It is worth noting that while the company reported an improvement in its financial performance, it remains highly speculative due to its small size and lack of track record. Investors should therefore carefully analyze Karyopharm Therapeutics before committing to an investment.
